The number-one question we hear from patients who are candidates for GLP-1 medications is not "will this work?" It is "how much is this going to cost me?" We respect that, and we are not going to pretend the answer is simple. The cost reality for these drugs is genuinely complicated — it depends on your insurance, your diagnosis, the specific medication, and sometimes even which pharmacy you use. This article walks through all of it honestly.
Sticker price vs. what you actually pay
The cash price for brand-name GLP-1 medications without any insurance or discount is roughly $1,000 to $1,400 per month. Ozempic (semaglutide for diabetes) runs about $1,000. Mounjaro and Zepbound (tirzepatide) are in the $1,050–$1,100 range. Wegovy (higher-dose semaglutide for weight loss) sits around $1,350. These numbers feel alarming — and they are meant to. But almost nobody pays full sticker price. Insurance coverage, manufacturer savings cards, and direct-to-consumer programs can bring monthly costs down to $25 to $400 for most patients. The path to that lower number is what we help you find.
Coverage for Type 2 diabetes: Ozempic, Mounjaro, Trulicity
If you have Type 2 diabetes, you have the most favorable coverage environment. Most commercial insurance plans cover at least one GLP-1 medication for diabetes — but they choose which one is "preferred" on their formulary, and it varies by plan and year. Prior authorization is the norm, not the exception. That means your insurer wants us to submit paperwork documenting your diagnosis, your A1C, and what you have already tried before they approve the medication. We do this as part of standard care — you should not have to chase this paperwork yourself.
Step therapy is also common. Many plans require that you have already tried metformin (and sometimes a second oral medication) before they will approve a GLP-1. If you have tried and failed those medications, we document it. If you have not tried them, we discuss whether it makes sense medically to work through the required sequence.
With commercial insurance and prior authorization approved, the typical patient copay for a GLP-1 diabetes medication is $25 to $100 per month. Medicare Part D covers Ozempic and Mounjaro for diabetes — the exact amount you pay depends on your specific Part D plan and which coverage phase you are in, but it is often less than cash price. Texas Medicaid covers some GLP-1 medications depending on your managed care organization; we check this with you individually.
Coverage for weight loss: Wegovy, Zepbound, Saxenda
This is where it gets harder. Many commercial insurance plans specifically exclude weight-loss medications from coverage — it is often buried in the fine print of your pharmacy benefits. Medicare does not cover any weight-loss medications by federal statute, though legislation to change that has been introduced and may eventually pass. Employer-sponsored plans vary widely: some larger self-insured employers have added GLP-1 coverage for obesity, others have not. The only way to know is to check your prescription benefits page or call the number on the back of your insurance card and ask specifically about your plan's obesity medication benefit.
If your plan does cover a weight-loss GLP-1 with prior authorization, your copay is usually $25 to $150 per month. If it does not cover it, that is where the options below become relevant.
Manufacturer savings cards
Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) both offer savings programs for commercially insured patients. The typical structure: $25 per month for qualified patients. Saxenda (liraglutide for weight loss) has a less generous program but one exists.
The critical limitation: these cards are not available if you have government insurance — Medicare, Medicaid, TRICARE, or any federal program. The manufacturer programs are specifically for commercially insured patients who still have a copay or coinsurance. Eligibility is re-verified annually, and most programs have a 12-month cap before requiring re-enrollment. We help coordinate savings card enrollment with your pharmacy when applicable.
Eli Lilly has also launched Lilly Direct, a direct-to-consumer program that sells Zepbound in vial form (not the standard auto-inject pen) at a lower cash price — around $399 per month for higher doses, $179 for lower. The vials require drawing your own dose, which is not for everyone, but for cash-pay patients it is a meaningful option. This is a legitimate Lilly program, not a third-party shortcut.
The compounded GLP-1 question
Over the past two years, a cottage industry of compounding pharmacies emerged selling semaglutide and tirzepatide at lower prices, taking advantage of FDA shortage provisions that allowed compounding when a drug was officially on the shortage list. The FDA declared the semaglutide shortage resolved in early 2025 and the tirzepatide shortage resolved before that. Under federal law, once the shortage is resolved, compounding pharmacies are no longer legally permitted to compound copies of those medications under the shortage exemption.
A few additional facts worth knowing: the quality of compounded GLP-1s has varied enormously. Some compounders are accredited 503B facilities with rigorous quality standards. Many are not. Some are selling a salt form of semaglutide (semaglutide sodium or semaglutide acetate) rather than the base molecule — these are not bioequivalent to the approved drug and have not been studied for efficacy or safety. Dosing instructions have also varied widely across compounders, sometimes in ways that increase side effect risk.
Our position is straightforward: we do not prescribe compounded GLP-1 medications. If you are currently on one when you come to see us, we will have an honest conversation about the risks and work together on a transition plan. We are not here to judge the decision — we understand cost drives a lot of these choices — but we can only take clinical responsibility for medications we know are what they say they are.
Strategies if you are uninsured or your plan does not cover weight-loss medications
- Lilly Direct vials — The most concrete cash-pay option for tirzepatide. Around $399/month for higher doses, with a savings card option for the first month. Visit lillydirect.com directly.
- Manufacturer Patient Assistance Programs (PAPs) — Both Novo Nordisk and Lilly have programs for patients who meet income criteria and are uninsured or underinsured. These require an application and income documentation, but they can provide the medication at no cost. We can help initiate the application.
- Older GLP-1 medications — Trulicity (dulaglutide) and Victoza (liraglutide for diabetes) are older, sometimes have better generic-adjacent pricing, and may fit your formulary differently. They are clinically effective, especially for blood sugar control.
- Rybelsus (oral semaglutide) — A pill form of semaglutide approved for Type 2 diabetes. Some insurance plans cover it differently than injectable Ozempic. Not approved for weight loss, but if diabetes treatment is the goal, it is worth checking.
What we can do for you
We run prior authorizations as part of standard care — you do not pay separately for that work. When a PA is denied and there is a medical basis to appeal, we appeal. We will switch your prescription to a covered alternative if your formulary changes or your insurer prefers a different agent. We coordinate with your pharmacy on savings card enrollment. And when the answer is honestly "there is no good covered option," we will tell you that directly and go through the real cash-pay math with you so you can decide.
What we do not recommend
- "Online GLP-1 clinics" that prescribe after a 5-minute questionnaire without reviewing your full medical history, labs, or cardiovascular risk. GLP-1 medications are effective but not without contraindications — they require real clinical evaluation.
- Compounded GLP-1s from sources you cannot verify, for the reasons described above.
- Stopping your medication abruptly because of cost. Weight regain after stopping GLP-1s happens quickly — often within weeks. If cost becomes a barrier, call us before stopping. We may be able to switch you to something more affordable, titrate down slowly, or find a short-term bridge.
Before you start: a practical checklist
- Confirm your insurance benefit — specifically ask about your plan's obesity and diabetes medication tiers. We help with this.
- Review the prior authorization criteria your insurer uses — we can tell you what they typically require.
- Check savings card eligibility before your first fill.
- Plan for the long term. GLP-1 medications work while you take them — for most patients, this is a long-term commitment, not a 90-day prescription. Factor ongoing monthly cost into that decision.
Coverage and cost change frequently; this article reflects 2026 norms and our best current knowledge. We can verify your specific plan in a few minutes — it is one of the first things we do when we discuss starting one of these medications.
If you are trying to figure out whether a GLP-1 is affordable for your situation, call us. We will do the insurance legwork before you commit to anything.